Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin201262102922237781
   PubMed Web of Science ®Google Scholar
• AzzoliCGBakerSJrTeminS[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.]Zhongguo Fei Ai Za Zhi200913171189 Chinese20681066
   PubMedGoogle Scholar
• D’AddarioGFruhMReckMBaumannPKlepetkoWFelipEMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v116v11920555059
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 2.2013 Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed March 21, 2013
   Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci USA2004101133061331115329413
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• Cortes-FunesHGomezCRosellREpidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsAnn Oncol2005161081108615851406
   PubMed Web of Science ®Google Scholar
• MitsudomiTKosakaTEndohHMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol2005232513252015738541
   PubMed Web of Science ®Google Scholar
• HanSWKimTYJeonYKOptimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylationClin Cancer Res2006122538254416638863
   PubMed Web of Science ®Google Scholar
• InoueASuzukiTFukuharaTProspective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutationsJ Clin Oncol2006243340334616785471
   PubMed Web of Science ®Google Scholar
• SugioKUramotoHOnitsukaTProspective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutationsLung Cancer20096431431818992959
   PubMed Web of Science ®Google Scholar
• SunagaNTomizawaYYanagitaniNPhase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapyLung Cancer20075638338917368623
   PubMed Web of Science ®Google Scholar
• SutaniANagaiYUdagawaKGefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clampBr J Cancer2006951483148917106442
   PubMed Web of Science ®Google Scholar
• TamuraKOkamotoIKashiiTMulticentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)Br J Cancer20089890791418283321
   PubMed Web of Science ®Google Scholar
• YoshidaKYatabeYParkJYProspective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancerJ Thorac Oncol20072222817410005
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol2008262442244918458038
   PubMed Web of Science ®Google Scholar
• MoritaSOkamotoIKobayashiKCombined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutationsClin Cancer Res2009154493449819531624
   PubMed Web of Science ®Google Scholar
• JackmanDMMillerVACioffrediLAImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsClin Cancer Res2009155267527319671843
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol2012301122112822370314
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol2011292866287421670455
   PubMed Web of Science ®Google Scholar
• GridelliCDe MarinisFDi MaioMCortinovisDCappuzzoFMokTGefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issuesLung Cancer2011723821216488
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYUpdated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol201230Suppl7521
   Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol201324545922967997
   PubMed Web of Science ®Google Scholar
• OizumiSKobayashiKInoueAQuality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 TrialOncologist20121786387022581822
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• YangJCHSchulerMHYamamotoNLUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsJ Clin Oncol201230SupplLBA7500
   Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
   PubMed Web of Science ®Google Scholar
• TakanoTFukuiTOheYEGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in JapanJ Clin Oncol2008265589559518794545
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052e7315737014
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res2006126494650117085664
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res2006125764576917020982
   PubMed Web of Science ®Google Scholar
• ToyookaSKiuraKMitsudomiTEGFR mutation and response of lung cancer to gefitinibN Engl J Med20053522136 author reply 213615901872
   PubMed Web of Science ®Google Scholar
• HallJGEisPSLawSMSensitive detection of DNA polymorphisms by the serial invasive signal amplification reactionProc Natl Acad Sci USA2000978272827710890904
   PubMed Web of Science ®Google Scholar
• NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res2005657276728216105816
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med200835936637718596266
   PubMed Web of Science ®Google Scholar
• SuKYChenHYLiKCPretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerJ Clin Oncol20123043344022215752
   PubMed Web of Science ®Google Scholar
• BranfordSRudzkiZWalshSHigh frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood2002993472347511964322
   PubMed Web of Science ®Google Scholar
• TamboriniEBonadimanLGrecoAA new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patientGastroenterology200412729429915236194
   PubMed Web of Science ®Google Scholar
• KumarAPetriETHalmosBBoggonTJStructure and clinical relevance of the epidermal growth factor receptor in human cancerJ Clin Oncol2008261742175118375904
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA20081052070207518227510
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene2008274702471118408761
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKGaleCMPF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res200767119241193218089823
   PubMed Web of Science ®Google Scholar
• GonzalesAJHookKEAlthausIWAntitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorMol Cancer Ther200871880188918606718
   PubMed Web of Science ®Google Scholar
• SosMLRodeHBHeynckSChemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutationCancer Res20107086887420103621
   PubMed Web of Science ®Google Scholar
• TakezawaKOkamotoITanizakiJEnhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptorMol Cancer Ther201091647165620530710
   PubMed Web of Science ®Google Scholar
• RegalesLGongYShenRDual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerJ Clin Invest20091193000301019759520
   PubMed Web of Science ®Google Scholar
• ShimamuraTLiDJiHHsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceCancer Res2008685827583818632637
   PubMed Web of Science ®Google Scholar
• ZhouWErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature20094621070107420033049
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• OuSHIGovindanREatonKDPhase I/II dose-finding study of crizotinib (criz) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl2610
   Google Scholar
• YoshidaTOkamotoIOkamotoWEffects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplificationCancer Sci201010116717219804422
   PubMed Web of Science ®Google Scholar
• OkabeTOkamotoITsukiokaSAddition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplificationClin Cancer Res20091590791319188161
   PubMed Web of Science ®Google Scholar
• MorgilloFWooJKKimESHongWKLeeHYHeterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinibCancer Res200666101001011117047074
   PubMed Web of Science ®Google Scholar
• MorgilloFKimWYKimESCiardielloFHongWKLeeHYImplication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res2007132795280317473213
   PubMed Web of Science ®Google Scholar
• GuixMFaberACWangSEAcquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsJ Clin Invest20081182609261918568074
   PubMed Web of Science ®Google Scholar
• SosMLKokerMWeirBAPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRCancer Res2009693256326119351834
   PubMed Web of Science ®Google Scholar
• YamasakiFJohansenMJZhangDAcquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated AktCancer Res2007675779578817575145
   PubMed Web of Science ®Google Scholar
• ZakowskiMFLadanyiMKrisMGMemorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome GroupEGFR mutations in small-cell lung cancers in patients who have never smokedN Engl J Med200635521321516837691
   PubMed Web of Science ®Google Scholar
• ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res2011171169118021248300
   PubMed Web of Science ®Google Scholar
• MorinagaROkamotoIFurutaKSequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutationLung Cancer20075841141317601631
   PubMed Web of Science ®Google Scholar
• YanoSWangWLiQHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res2008689479948719010923
   PubMed Web of Science ®Google Scholar
• YaoZFenoglioSGaoDCTGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProc Natl Acad Sci USA2010107155351554020713723
   PubMed Web of Science ®Google Scholar
• SudaKTomizawaKFujiiMEpithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinibJ Thorac Oncol201161152116121597390
   PubMed Web of Science ®Google Scholar
• UramotoHShimokawaHHanagiriTKuwanoMOnoMExpression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinomaLung Cancer20113025132517
   Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med2011375ra26
   PubMed Web of Science ®Google Scholar
• PalmerRHVernerssonEGrabbeCHallbergBAnaplastic lymphoma kinase: signalling in development and diseaseBiochem J200942034536119459784
   PubMed Web of Science ®Google Scholar
• ManoHNon-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancerCancer Sci2008992349235519032370
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• ChoiYLTakeuchiKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerCancer Res2008684971497618593892
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLSodaMMultiplex reverse transcription-PCR screening for EML4-ALK fusion transcriptsClin Cancer Res2008146618662418927303
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res2009153143314919383809
   PubMed Web of Science ®Google Scholar
• SolomonBVarella-GarciaMCamidgeDRALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerJ Thorac Oncol200941450145420009909
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469
   PubMed Web of Science ®Google Scholar
• WongDWLeungELSoKKThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer20091151723173319170230
   PubMed Web of Science ®Google Scholar
• TiseoMGelsominoFBoggianiDEGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer20117124124321168933
   PubMed Web of Science ®Google Scholar
• Mino-KenudsonMChirieacLRLawKA novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryClin Cancer Res2010161561157120179225
   PubMed Web of Science ®Google Scholar
• RodigSJMino-KenudsonMDacicSUnique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationClin Cancer Res2009155216522319671850
   PubMed Web of Science ®Google Scholar
• YoshidaATsutaKNakamuraHComprehensive histologic analysis of ALK-rearranged lung carcinomasAm J Surg Pathol2011351226123421753699
   PubMed Web of Science ®Google Scholar
• LinELiLGuanYExon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancersMol Cancer Res200971466147619737969
   PubMed Web of Science ®Google Scholar
• SugawaraETogashiYKurodaNIdentification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer methodCancer20121184427443622252991
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther200763314332218089725
   PubMed Web of Science ®Google Scholar
• ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res2007674408441717483355
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1studyLancet Oncol2012131011101922954507
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKPhase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007)Ann Oncol201223Suppl 9ixe21
   Google Scholar
• KimDWAhnMJShiYUpdated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancerAnn Oncol201223Suppl 9ix400ix446
   Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell20111967969021575866
   PubMed Web of Science ®Google Scholar
• KiuraKSetoTYamamotoNA first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLCJ Clin Oncol201230Suppl7602
   Google Scholar
• NishioMKiuraKNakagawaKA phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portionAnn Oncol201223Suppl 9ix152ix174
   Google Scholar
• ShawATCamidgeDRFelipEResults of a first-in-human phase I study of the ALK INHIBITOR LDK378 in advanced solid tumorsAnn Oncol201223Suppl 9ix152ix174
   Google Scholar
• CecconMMologniLBissonWScapozzaLGambacorti-PasseriniCCrizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitorsMol Cancer Res20121112213223239810
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci USA20111087535754021502504
   PubMed Web of Science ®Google Scholar
• GettingerSWeissGJSalgiaRA first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignanciesAnn Oncol201223Suppl 9ix152ix174
   Google Scholar
• LovlyCMHeuckmannJMde StanchinaEInsights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitorsCancer Res2011714920493121613408
   PubMed Web of Science ®Google Scholar
• KuromitsuSMoriMShimadaIAntitumor activities of ASP3026 against EML4-ALK-dependent tumor modelsMol Cancer Ther201110SupplA227
   Google Scholar